



**Vita Life Sciences Limited**

ACN 003 190 421

ABN 35 003 190 421

**Corporate Office**

Suite 802, Level 8,  
1-5 Chalmers Crescent  
Mascot NSW 2020  
Australia

T: 61 2 9545 2633

F: 61 2 9545 1311

[vitalifesciences.com](http://vitalifesciences.com)

22 May 2025

Market Announcements  
Australian Securities Exchange Ltd  
20 Bridge Street  
Sydney, NSW 2000

Dear Sir/ Madam,

**2025 ANNUAL GENERAL MEETING (AGM)-ADDRESS & PRESENTATION**

The Vita Life Sciences Ltd addresses to the 2025 AGM by the Chairman and the Managing Director, with related presentation is attached.

This announcement has been authorised for release by the Board.

Yours faithfully,

A handwritten signature in black ink, appearing to be 'Chin L Khoo', written in a cursive style.

Chin L Khoo  
Company Secretary  
Email: [enquiries@vitalifesciences.com.au](mailto:enquiries@vitalifesciences.com.au)

## **Vita Life Sciences Limited – 2025 Annual General Meeting**

### **Chairman's Script - 22 May 2025**

#### **Welcome**

Good morning ladies and gentlemen. I'm Henry Townsing, the Chairman of Vita Life Sciences Limited and the Chairman for the Annual General Meeting today.

Welcome to the VLS 2025 Annual General Meeting.

We are conducting this AGM physically in our new office, whereby shareholders may attend in person or observe only, via webinar facility managed by Automic. If you experience any difficulties with your connection to the AGM, you may contact our share registry, Automic on 1300 288 664.

It is now just after 11.30 am and, there being a quorum present, I declare the meeting has been properly constituted and open for business.

#### **Introduction**

I have pleasure in introducing my fellow Directors who are in attendance:

- Andrew O'Keefe, our Managing Director;
- Jack Teoh, a non-executive Director; and
- Peter Osborne, a non-executive director.

Also present is our Company Secretary and CFO, Mr Chin Khoo and the Company's external auditor representative via webinar, Mr Stephen Fisher the audit partner from Nexia. There will be opportunity for shareholders to ask questions to the Auditor as well as the Board on financial and business matters later in the meeting.

#### **OUTLINE OF MEETING**

Our business begins with the Managing Director's presentation and, then the formal items of business as set out in the Notice of Meeting.

I would like to welcome those shareholders that are observing us online and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your screen. When you submit a question or comment, please start by typing which resolution it relates to so that it can be addressed at the appropriate time.

Questions which relate to the general business of the Company will be collected and addressed after the close of the formal business of the meeting.

I will now hand over the meeting to Andrew O'Keefe, our Managing Director who will be presenting a report on the Company's business.

### **Andrew O'Keefe**

Thank you, Henry for the introduction.

### **AGENDA 1 MANAGING DIRECTORS PRESENTATION**

Refer to Managing Directors Presentation

*[Upon Completion of MD's Presentation Andrew, hands the conduct of the meeting to the Chairman]*

### **AGENDA 2 RESOLUTIONS**

Thank you, Andrew for that presentation. We shall now commence the formal business of the meeting.

The Notice of Annual General Meeting was announced to all members and the ASX on 17 April 2025 and is to be taken as read. Voting on all resolutions, will be conducted by poll.

For the purposes of the poll, I appoint the representative of Automic, the Company's share registry, who has examined and prepared summaries of the proxy forms received, to act as Returning Officer and to conduct the poll.

Shareholders observing online who have **already submitted their votes by proxy** should note that your votes will already be counted towards the poll.

The proxies have been inspected and all those validly lodged have been accepted.

Proxies have been received representing up to 35,534,677 Shares or around 63% of the issued capital of the Company.

All undirected proxies or open votes that have nominated the Chairman of the Meeting as their proxy, will be cast in favour of each resolution.

We will now proceed to the resolutions set out in the Notice of AGM.

### **Financial Statements and Reports of Directors and Auditors**

I turn now to the first item of business on the agenda, the consideration of the Financial Statements and Reports. The financial report and the reports of the directors and the auditors are now laid before the meeting. There will be no vote on this item as it is a discussion item only.

The Company's auditor for the 2024 financial year, **Mr Stephen Fisher** of Nexia Sydney Audit Pty Ltd is available to take questions relevant to the conduct of the audit and the preparation and content of the independent auditor's report.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

Is there any discussion or questions on the 2024 Financial Reports?

Are there any questions relevant to the conduct of the audit and the preparation and content of the auditor's report to be put to the auditor?

### ***[PAUSE AND TAKE QUESTIONS]***

If there are no further question, I declare that the reports have been received and considered at this meeting.

## **Remuneration Report**

In accordance with the Notice of Meeting, I now move onto item 2, Resolution 1 which is as follows:

*To consider and, if thought fit, to pass, with or without amendment, **Resolution 1**, Adoption of the Remuneration Report for the Financial year ended 31 December 2024, as an **ordinary resolution**.*

I note that while the vote on this item is advisory only and does not bind the Company nor its directors, the Board and Remuneration Committee takes into consideration the feedback we receive from shareholders.

An explanation of the item is to be found on page 9 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please raise your hands or submit your questions via the Q&A function.

### **[PAUSE AND TAKE QUESTIONS]**

Members of the Company's key management personnel who were named in the FY2024 remuneration report and their closely related parties are reminded that they may not vote on this resolution.

If there are no further questions I will move to the next resolution.

## **Resolution 2: Re-election of Director – Mr Henry Townsing**

I put forward Resolution 2:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 2**, as an **ordinary resolution**.

*“That Henry Townsing, a director retiring by rotation in accordance with clause 14.4 of the Constitution, being eligible and having consented to act, be re-elected as a director of the Company.”*

An explanation of Resolution 2 and information on Mr. Townsing is found on page 10 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please raise your hands or submit your questions via the Q&A.

***[PAUSE AND TAKE QUESTIONS]***

If there are no further questions I shall move to the next resolution.

**Resolution 3: Aggregate Annual Remuneration Payable to Non-Executive Directors  
be Increased to Maximum of \$300,000 from Year 2026**

To consider and, if thought fit, to pass, with or without amendment, **Resolution 3**, as an **ordinary resolution**.

*“That in accordance with Listing Rule 10.17 of the Official Listing Rules of the ASX Limited and Clause 14.5 of the Company's Constitution, the total aggregate annual remuneration payable to non-executive Directors of the Company be increased by \$100,000 per annum, from \$200,000 per annum to a maximum of \$300,000 per annum effective from 1 January 2026.”*

An explanation of Resolution 3 is found on page 10 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please raise your hands or submit your questions via the Q&A.

**[PAUSE AND TAKE QUESTIONS]**

Members of the Company's Board of Directors and their closely related parties are reminded that they may not vote on this resolution.

If there are no further questions I shall move to the next resolution.

**Resolution 4: Share-Buy Back**

I put forward Resolution 4:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 4**, as an **ordinary resolution**.

*"That pursuant to and in accordance with section 257C of the Corporations Act 2001 (C'wlth), as amended, Rules 7.29 and 7.33 of the Listing Rules of ASX Limited, and for all other purposes, the shareholders approve, with effect from when the Directors make the relevant announcement to the ASX, the on-market buy-back of up to 15% of the fully paid ordinary shares in the Company expiring on whichever is the earlier of the anniversary of the passage of this resolution or the 2026 Annual General Meeting and otherwise on the terms and conditions set out in the Explanatory Statement accompanying the 2025 Annual General Notice of Meeting at which this resolution is to be put."*

An explanation of Resolution 4 and information the share buy-back, is found from page 11 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please raise your hands or submit your questions via the Q&A.

***[PAUSE AND TAKE QUESTIONS]***

Ladies and gentlemen, that concludes the resolutions to be voted. As mentioned, we are conducting a Poll on all resolutions. For this purpose, I appoint Mathew Hunter of Automic Registry Services shall be the Returning Officer.

When you registered your attendance, voting shareholders and proxy holders were given a Yellow voting card. On this card you will find a series of boxes for voting. For your vote to count, you must tick or mark the corresponding “For”, “Against” or “Abstain” boxes.

As a proxyholder, when completing the voting card on the poll, you need only mark a box, if you have “discretionary” votes.

When voting is completed, staff from Automic will collect your voting cards.

I now ask that you complete your voting cards for all resolutions.

If there are any shareholders who have not handed in the voting card and if you wish to do so, kindly raise your hand.

**I shall now declare voting is closed.**

The staff of Automic will now collect the voting cards and process the poll. The results will be announced to the ASX once available.

If you have any questions, please raise your hands or submit your questions via the Q&A.

If there are no further questions I shall move to the next item.

**AGENDA 3 OTHER BUSINESS & QUESTION TIME**

Is there any other business that can lawfully be brought forward?

***[PAUSE TO CONSIDER]***

If there are none, I now invite shareholders to raise their hand if there are any questions for management or the auditor, or submit it via the Q&A function.



***[PAUSE AND TAKE QUESTIONS]***

**MEETING CLOSE**

There being no further questions or matters for discussion, I'd like to thank all shareholders for their attendance and will now end the today's meeting. I declare the meeting closed.

## **Vita Life Sciences Limited – 2025 Annual General Meeting**

### **Address by the Managing Director – 22<sup>nd</sup> May 2025**

#### **Opening remarks**

Good morning and a warm welcome to all shareholders, VLS directors and the Executive Team.

Thank you for joining the Company's Annual General Meeting. It is my pleasure to provide you with an update on the Company's performance and insights into the future direction of the company.

It's very pleasing to say that despite challenging global economic conditions, the Company has delivered once again a consistent performance by delivering on record revenue, whilst deploying several new initiatives across key strategic partnerships.

#### **About Vita Life Sciences**

The Vita Life Sciences Group has grown into one of Australia's and Southeast Asia's leading healthcare organisations.

The Group enjoys distribution coverage spanning six countries and is one of the few businesses in this category listed on the Australian Stock Exchange. All products within our portfolio are produced with the highest quality standards in both sourcing and manufacturing, supported by both scientific and traditional evidence.

The Group's purpose has never wavered, which is to provide consumers with trusted products that provide the opportunity to improve overall health and wellbeing.

#### **Operational Insights**

We are pleased to report that the Group has achieved another record revenue performance, underpinned by strong results in our key markets: Australia, Malaysia, and Singapore. Our strategic focus on expanding distribution channels, alongside increased investment in brand and retail support, has successfully stimulated consumer offtake.

In conjunction with the Group's aspirations to expand its market presence, we have launched Herbs of Gold in Vietnam and signed a new distribution partnership in China. While these business units are at different stages of their development the long-term opportunities in both markets remain highly promising.

Turning to the financial performance, the VLS Group delivered sales of \$79.5 million, up 8.3% from the prior corresponding period (PCP), and a pre-tax profit of \$12.6 million, up 1.5% from the PCP.

Our balance sheet remains strong, with total equity of \$52.3 million, up from \$43.3 million, and net cash of \$28.6 million, without any borrowings.

Based on sustained margins and profit performance, we declared a total dividend payment of 10 cents per share for FY24, up 11.1% on PCP.

I would like to now like to introduce you to Melissa Pereira – Group Head of Marketing who will provide an updated positioning of our brands.

### **Melissa Pereira – Head of Marketing**

Thank you, Andrew.

Today I'll take just a few minutes to give you a high-level overview of two key brands in our portfolio – *Herbs of Gold* and *VitaHealth* – and how they are positioned to meet the evolving needs of our customers across regions.

### **Brand Positioning – Herbs of Gold**

Starting with Herbs of Gold, our Australian flagship brand.

Herbs of Gold has been proudly supporting health and wellness since 1989. We're known for high-quality, therapeutic formulations that blend the wisdom of traditional herbal medicine with modern nutritional science.

Herbs of Gold is premium priced and positioned. In the Australian market, Herbs of Gold has been a leader in creating this 'high-end' positioning in the vitamins and supplements category. To support our positioning strategy, 2024 saw an education-led approach amongst customers and consumers – helping them understand our therapeutic formulations – as was seen in our TV advertorials across channel 9 and channel 7.

### **Brand Positioning – VitaHealth**

Moving on to VitaHealth, our Southeast Asian powerhouse brand.

VitaHealth, the retail brand, was established in 1973. It combines science-backed innovation with a deep understanding of local consumer needs.

In 2024, we wanted to truly showcase how much the brand cares for the community and people. We delivered 9 major marketing and community events, as well as entered into 4 new corporate partnerships – with Penang State Sports Council, Anytime Fitness, D Swim Academy and Sports Nutrition Academy.

### **2024 NPD**

2024 was another proud year for us as a group. With over 350 products registered across the business, we delivered an additional 16 new products across Australia, Malaysia and Singapore. Our product roadmap is designed to address emerging health trends and consumer needs. To provide a better sense of our product innovation and brand, we have showcased a couple products and ranges in the coming slides.

### **Product showcase – Sea Buckthorn Oil**

Herbs of Gold Sea Buckthorn Oil is a focus product in the Australian business. A relatively unique ingredient, Herbs of Gold was the first brand to launch it in capsule format, over the counter. Herbs of Gold Sea Buckthorn Oil contains Omegia, a high-grade, sustainably sourced Sea buckthorn oil that provides a balanced profile of omega 3, 6, 7 and 9 fatty acids – a non-fish source suitable for vegans and vegetarians. Positioned for dry eye relief and skin hydration, Herbs of Gold Sea Buckthorn Oil will have a large above-the-line push in Q3 2025.

### **Product showcase – Ashwagandha Plus**

VitaHealth Charge-Up Ashwagandha Plus is a focus product in the Malaysian business. Positioned for stress and anxiety relief, Ashwagandha Plus is a synergistic combination of KSM-66 ashwagandha extract (reducing cortisol) and saffron extract (boosting happy hormones). Ashwagandha Plus forms part of the VitaHealth's Charge-Up range, Malaysia's first mental wellness range.

### **Range showcase – VitaHealth V-Style**

In 2024, we saw the launch of a new range in Malaysia, VitaHealth V-Style. Exclusive distribution to Watsons, the range includes 4 products in the fitness and post-workout space. The range was launched to meet the growing consumer demand – Euromonitor 2024 Malaysia report highlights sport nutrition in dynamic growth with retail value sales rising by 17%. To celebrate and promote the launch, Pearly Tan, an Olympic badminton player, was appointed an official ambassador.

### **2024 Awards**

Our efforts across service, marketing and product, were officially recognised as we won 13 prestigious industry awards in 2024. As we reflect on these achievements, it's clear that our integrated approach to product development, service, operations and marketing is resonating with both industry peers and consumers. These awards validate our strategies and inspire us to continue to push boundaries in the health and wellness sector.

I'll now hand back to Andrew for the remainder of the presentation.

### **Social Impact and corporate responsibility**

At Vita Life Sciences, we are committed to strengthening our Environmental, Social, and Governance (ESG) strategy by integrating key initiatives into our core business operations. These efforts reflect our dedication to making a meaningful and lasting impact on the communities and customers we serve. Our goal is to drive sustainable growth through long-term strategies that benefit both our business and the planet.

### **Strategic Priorities**

The Company continues to demonstrate prudent financial discipline. Our business maintains a strong balance sheet and an even stronger cash position. We will continue to invest across key strategic pillars and leverage market potential.

The business has a consistent history of delivering on our long-term strategic goals. We will remain focuses of 4 primary pillars including:

1. Brand Building - leveraging off our community lead marketing campaigns across domestic markets
2. Education and training – embedding the national training portal across the Australian market
3. Strategic Expansion – increased investment and support in Vietnam and China business units
4. Operation leverage – maintain strong NPD pipeline leveraging scale and reach

Over the next 12 months, we will continue to build on our four key strategic pillars, reinvesting in the business to positively impact our performance.

In closing, I would like to thank all our shareholders and customers once again; without them, we wouldn't be in the strong position we are today.

Thank you for your attention. I will now hand the meeting back to the Chairman.

**Andrew O'Keefe**  
Managing Director



Annual General Meeting  
22 May 2025





Chairman

## Henry Townsing

Mr Townsing brings over 30 years' experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011. Mr Townsing was appointed as the Chairman of the Company effective 28th May 2021 and is also the chairman of the Company's Board Nomination and Remuneration Committees.







## Managing Director **Andrew O'Keefe**

We are pleased to provide our shareholders with an update on the Company's performance for the 2024 financial year, along with key operational insights. Over the past 12 months, the Company has delivered consistent and robust results, underscoring the strength of our strategic direction and extensive product offerings. Despite challenging global economic conditions, the Group's full-year performance highlights the resilience and effectiveness of our approach.





# Our people

We have over 350 employees in the Vita Life Sciences Group across Australia, Malaysia, Singapore, China, Indonesia and Vietnam. We have teams of qualified naturopaths, nutritionists, herbalists, biotechnologists, and pharmacists. and online retailers in the health food and pharmacy sector.

OVER  
**350**  
EMPLOYEES

# Our markets

We continue to evolve and expand our global presence.  
We are currently in 6 markets.

AUSTRALIA  
MALAYSIA  
SINGAPORE  
VIETNAM  
INDONESIA  
CHINA

# Our partners

Our products are available across some of the biggest offline and online retailers in the health food and pharmacy sector.





# Operational insights


**RECORD REVENUE GROWTH:** The Group achieved record revenue, supported by moderate growth across the Australian, Malaysian, and Singaporean markets.

**FINANCIAL STRENGTH:** The Group maintains a strong financial position with \$52.3 million in equity and \$28.6 million in cash reserves. The company remains debt-free with no bank borrowings.

## KEY INITIATIVES:

- Herbs of Gold brand officially launched in Vietnam, with exclusive distribution through ConCung network of over 600 mother and baby retail stores, significantly enhancing brand visibility and market entry.
- A new distribution agreement signed with Rou Yu Chen in December, strengthening our presence in China.
- Delivered a robust pipeline of 16 new product across the VitaHealth and Herbs of Gold brands, supporting continued growth and innovation.

**DIVIDEND ANNOUNCEMENT:** A fully franked dividend of 10.0 cents per share for the financial period.



The group maintains a strong balance sheet with equity of \$52.3M and cash reserves of \$28.6M, with no bank borrowings.



Head of Marketing  
**Melissa Pereira**





# Brand Positioning

herbsofgold™

Herbs of Gold delivers a high-end, therapeutic product to consumers. The product imagery and advertising efforts reflect premium positioning. In 2024, we focussed on strengthening this strategy, coupling it with education for the trade and consumers on our complex and intelligently crafted formulations.







# Brand Positioning



VitaHealth has been a people-focussed and trusted brand for over 50 years. We continue to position VitaHealth as the brand that genuinely cares. 2024 pushed this positioning further by delivering 9 major marketing and community events, as well as, entering into 4 new corporate partnerships.





There are currently over  
**350 products**  
registered across the  
business.

**2024 NPD**

**16 new products**  
launched across Australia,  
Malaysia and Singapore.



## Australia

Herbs of Gold Magnesium Powder High Strength  
Herbs of Gold Magnesium Night  
Herbs of Gold L-Theanine 200mg  
Herbs of Gold Zinc Chewable  
Herbs of Gold Vitamin D3 Liquid



## Malaysia

VitaHealth Kids Sambukid  
VitaHealth V-Style Magnesium 300mg  
VitaHealth V-Style Magnesium AT + K2  
VitaHealth V-Style Post-Workout  
VitaHealth V-Style Pre-Boost  
Herbs of Gold Cabbage Ezenze  
Herbs of Gold NMN Suprme



## Singapore

VitaHealth Kids Sambukid  
VitaHealth Charge-Up Mag-Ease  
VitaHealth Charge-Up Ultra Sleep Well  
VitaHealth NMN+

# Product showcase



## Herbs of Gold Sea Buckthorn Oil

- Contains Omega™, a high-grade, sustainably sourced Sea buckthorn oil that provides a balanced profile of omega-3, 6, 7 and 9 fatty acids – a non-fish source, suitable for vegans and vegetarians.
- Relieves dry eyes and supports skin hydration and health.
- 100% organic sea buckthorn oil


herbs of gold™



Herbs of Gold was the first brand to launch Sea Buckthorn Oil in capsule format, over-the-counter, in Australia. This product will have a major above-the-line push in Q3 2025.



# Product showcase



## VitaHealth Charge-Up Ashwagandha Plus

- Stress & anxiety relief
- Synergistic combination of KSM-66 ashwagandha extract (reduces cortisol) & saffron extract (boosts happy hormones)
- Convenient one-a-day dose
- Boosts mood & improves sleep quality



VitaHealth leads the way with Charge-Up, Malaysia's first mental wellness range, made for life's daily pressures.

# Range showcase



## VitaHealth V-Style

- Launch in 2024.
- Exclusive to Watsons in Malaysia.
- Fitness and post-workout range – 4 products in total.
  - Meeting consumer need - Euromonitor 2024 Malaysia report highlighted sports nutrition in dynamic growth with retail value sales rising by 17%.
  - Pearly Tan (Olympic badminton player) official ambassador for the launch of VitaHealth V-Style.





## MALAYSIAN BUSINESS OF THE YEAR

THE STAR OUTSTANDING BUSINESS AWARDS 2024  
- MALAYSIA



## CONSUMERS' CHOICE

- SINGAPORE

herbs of gold™

## VOICE OF THE CUSTOMER

ADVANTAGE PHARMACY PROGRAM  
- AUSTRALIA



## 2024 Awards

### AUSTRALIA

VOICE OF THE CUSTOMER – ADVANTAGE PHARMACY PROGRAM 2024  
NATURAL HEALTH SUPPLIER OF THE YEAR – WHOLELIFE PHARMACY & HEALTHFOODS  
TOP GROWTH PERFORMER – CHEMIST OUTLET AWARDS

### MALAYSIA

MALAYSIAN BUSINESS OF THE YEAR – THE STAR OUTSTANDING BUSINESS AWARDS (SOBA)  
BEST HALAL PRODUCT (PLATINUM) – THE STAR OUTSTANDING BUSINESS AWARDS (SOBA)  
BEST BRAND (MERITORIOUS BRONZE) – THE STAR OUTSTANDING BUSINESS AWARDS (SOBA)  
BEST IN CSR (SILVER) – THE STAR OUTSTANDING BUSINESS AWARDS (SOBA)  
BEST SALES IMPROVEMENT AWARD IN HEALTH CARE – GUARDIAN  
BEST SELLER AWARD IN SKIN HEALTH FOR SKINTRU – GUARDIAN  
FAN FAVOURITES AWARD IN EYE CARE FOR BILBERRY & MARIGOLD PLUS – GUARDIAN

### SINGAPORE

CONSUMERS' CHOICE  
TOP SELLER, TURMERIC – SUPPLEMENTS UNITY POPULAR CHOICE AWARDS  
HEALTH PRODUCTS & SERVICES – BUSINESS REVIEW INTERNATIONAL BUSINESS AWARD



# Social impact & corporate responsibility



At Vita Life Sciences, we are dedicated to enhancing our Environmental, Social and Governance (ESG) strategy by embedding initiatives into our business operations to uphold the high standards we set for ourselves and our partners. We have developed partnerships with charities, launched team initiatives and are building programs to enhance education and literacy to further improve on this. These efforts reflect our commitment to making a positive impact on our communities. Our goal is to drive sustainable growth and create long-term strategies that benefit both our business and the planet.





# Strategic priorities





*Thank you*

# Resolutions

1. Remuneration Report
2. Re-election of Director – Mr Henry Townsing
3. Aggregate Annual Remuneration Payable to Non-Executive Directors to be increased to a maximum of \$300,000 from Year 2026
4. Share buy back

# Proxy-Resolution 1

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
1	Adoption of the Remuneration Report	19,724,424	85,222	6,298,540	8,608,643

# Proxy-Resolution 2

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
2	Re-election of Director (Henry Townsing)	29,183,993	48,144	6,298,540	-

# Proxy-Resolution 3

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
3	Aggregate Annual Remuneration Payable to Non-Executive Directors be increased to maximum of \$300,000 from Year 2026	20,121,222	89,722	6,298,540	8,435,693



# Proxy-Resolution 4

	RESOLUTIONS	IN FAVOUR	AGAINST	PROXY'S DISCRETION	EXCLUDED
4	Share buy-back	13,279,794	32,843	22,222,040	-

# Disclaimer

This document has been prepared by Vita Life Sciences Limited (**Vita Life Sciences or VLS**) and comprises written material/slides for a presentation concerning Vita Life Sciences.

The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Vita Life Sciences that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct, Except for any statutory liability which cannot be excluded, Vita Life Sciences and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Vita Life Sciences disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Vita Life Sciences since the date of this presentation.